<DOC>
	<DOCNO>NCT01034735</DOCNO>
	<brief_summary>The primary objective trial ass bioequivalence two concentration ( 5.83 mg/mL 8 mg/mL ) new r-hGH liquid multidose formulation use r hGH freeze-dried multidose formulation ( Saizen® 8 mg , 8.8 mg/1.51 mL ) reference . Each volunteer receive three r hGH treatment , treatment administer single subcutaneous dose 4 mg r-hGH randomize sequence least one week wash-out period successive treatment .</brief_summary>
	<brief_title>r-hGH Liquid Multidose Versus Freeze-dried Multidose Bioequivalence Trial</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Failure Thrive</mesh_term>
	<criteria>Main inclusion criterion : 1 . Male female age 18 45 year , inclusive ; able read , write fully understand German language 2 . Had give write Informed Consent 3 . Had body weight great 55 kg body mass index ( BMI ) &gt; 20 &lt; = 30 kg/m2 ( BMI = weight ( kg ) /height ( ) 2 ) 4 . Had vital sign follow normal range : Ear body temperature : 35.0 38.0°C Blood pressure ( BP ) least 3 minute rest , measure supine position : systolic blood pressure : 90 145 mmHg diastolic blood pressure : 50 95 mmHg Pulse rate ( PR ) : least 3 minute rest , measure supine position : 40 90 bpm 5 . Smoked less 10 cigarette per day , consent smoke le 5 cigarette per day trial period able refrain smoke confinement period 6 . Were able communicate well Investigator willing comply requirement entire trial 7 . Were willing undergo pituitary downregulation intravenous infusion somatostatin 25 hour If female : 8 . Had negative serum pregnancy test within three week prior trial start negative urine pregnancy test day dose 9 . Were premenopausal use adequate method nonhormonal contraception ( 2 barrier method , one barrier method spermicide , nonhormonal intrauterine device ) , sexual abstinence female vasectomise partner entire trial Main exclusion criterion : 1 . Any surgical medical condition , include finding medical history pre trial assessment , opinion Investigator , constitute risk contraindication participation subject trial could interfere trial objective , conduct evaluation 2 . Had clinically significant abnormal laboratory test result pretrial safety laboratory test clinically abnormal finding 12 lead rest electrocardiogram ( ECG ) opinion Investigator may increase safety risk subject 3 . Had positive result drug abuse alcohol test 4 . Had positive result serology examination Hepatitis B surface antigen ( HBsAg ) ( due vaccination ) , Hepatitis B core antibody ( HBcAb ) ( positive , verified test antiHbcIgM ) , Hepatitis C Virus ( antiHCV ) Human Immunodeficiency Virus ( antiHIV 1 2 ) screen 5 . History presence hypertension significant cardiovascular abnormality 6 . History presence cholelithiasis 7 . Significant history clinical evidence autoimmune , gastrointestinal , haematological , hematopoietic , hepatic , neurological , pancreatic renal disease 8 . History presence diabetes 9 . History presence tumor pituitary gland hypothalamus 10 . Definite suspect personal history family history adverse drug reaction hypersensitivity drug similar chemical structure somatropin somatostatin excipients , use chronic medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Saizen®</keyword>
	<keyword>bioequivalence</keyword>
	<keyword>recombinant human</keyword>
	<keyword>Growth Hormone</keyword>
	<keyword>treatment growth failure child</keyword>
	<keyword>growth hormone deficiency adult</keyword>
</DOC>